Khalid Islam
Independent Chairman of the BoardDr. Khalid Islam, Ph.D., served as the Director of Processa Pharmaceuticals, Inc since November 3, 2020 until July 11, 2022. He co-founded Sirius Healthcare Partners GmbH in 2009 and is its Partner. Dr. Islam is the Founder of Ki Consulting AG. He Co-Founded PrevAbr LLC in 2010. He founded Gain Therapeutics, Inc. in 2017 and has been its Chairman since 2017 and is also a director and shareholder of Elion Oncology, Inc. Dr. Islam has extensive international pharmaceutical expertise in transitioning companies from development to production. He is a Co-Founder of BioAim LLC. He is a founder/co-founder and Owner of Life Sciences Management GmbH. He is Managing Director of Life Sciences Management GmbH. since 2014. He serves as an Advisor of Venture Capital Group Kurma BioFund (Paris). He serves as an Advisor at Kurma Partners. Dr. Islam has experience in the pharmaceutical sector including at MTOM and HMR. He founded or co-founded several companies. From 1999 to 2008, he served as the President and Chief Executive Officer of Arpida AG. He served as the Chief Executive Officer at Gentium S.p.A. from November 2009 to January 23, 2014 and served as its President until January 2014, where he led the transition from a loss-making to a cash-flow positive and profitable company. He served as Senior Consultant of Arpida AG since January 2009. He served as the Chief Executive Officer of Arpida Ltd. from 2002 to May 1, 2008 and served as its President since 2002. He worked with Sanofi-Aventis (f/k/a HMR & MMD) from 1996 to 1999 and MMD from 1987 to 1996. He served as an Interim Scientific Director of Gentium S.p.A. from October 04, 2011 to March 2012. He served as an Interim Chief Executive Officer of Gentium S.p.A since November 2009. Dr. Islam held various leadership positions in research and development in Hoechst Marion Roussel (HMR) and Marion Merrell Dow (MMD). Dr. Islam has been Chairman of the Board at Minoryx Therapeutics s.l. since January 27, 2016. He served as Non-Executive Director at MolMed S.p.A. until May 2016. Dr. Islam is Independent Chairman of the Board of Fennec Pharmaceuticals Inc. from December 09, 2015. Dr. Islam joined the Fennec Pharmaceuticals Inc. on April 28, 2014. Dr. Islam served as a Director of Oxthera AB from 2014 to 2017. He has been a Director of Fennec Pharmaceuticals Inc. since April 28, 2014. Subsequent to the sale of Gentium, Dr. Islam has been involved from both an advisory and board level in several public and private healthcare related companies. He was an Independent Director of Karolinska Development AB (publ) since May 20, 2015 until 2017. Dr. Islam served as a Director of Immunomedics, Inc. since March 3, 2017 until October 23, 2020. He serves as a Member of the Editorial Board of Current Drug Discovery Technologies and the International Advisory Board of the Network of Excellence in Euro Patho Genomics. Dr. Islam serves as Member of the Academic Board for Doctorates and has supervised several M.Sc. and Ph.D. thesis. He serves as President of the Art Foundation Casaperlarte-Foundation Paolo Minoli. He is a Member of the International Scientific Board of the Network of Excellence in Pathogenomics. He served as Chairman of the Board at Gentium S.p.A from December 2009 to January 23, 2014. He served as a Director of Evolva Holding SA since May 2008. He served as a Director of Rheoscience AS (Copenhagen), Adenium AS (Copenhagen) and C10 Pharma AS (Oslo). He served as Chairman of Pcovery ApS from 2011 to 2015 and served as its Director since September 2011, C10 Pharma A/S from 2010 to 2014 and Molmed SpA from 2014 to 2016. He served as a Director of Arpida AG from 2002 to January 2009 and again served as Director from May 2008 to January 2009. He served as a Director of Gentium S.p.A from November 2009 to January 23, 2014. He served as an EMBO Research Fellow from 1985 to 1987 and MRC Research Fellow from 1983 to 1984 on cellular mechanisms for regulating protein: protein interactions. He served as a Research Assistant of Imperial College, University of London from 1978 to 1983. Dr. Islam held various positions, Leader of Strategic Alliance between HMR-Scriptgen, Coordinator of Biotechnology & High Throughput Screening, Group leader and Team Leader, with pre-clinical research & development of anti-infectives in major pharmaceutical companies. From 1977 to 1987, Dr. Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. He holds several patents and has published over 80 articles in leading journals. He serves as a Contract Professor of the University of Milan. He is trained in sciences. He received Diploma of Imperial College in Biophysics from Imperial College, University of London 1984. Dr. Islam received a Ph.D. in 1983 from Imperial College, University of London and a B.Sc. from Chelsea College in 1977.
Positions
- Company NameFennec Pharmaceuticals Inc.Stock CodeFENCPositionIndependent Chairman of the BoardColleagues
- JSJeffrey S. HackmanCEO & Director
- RCRobert C. AndradeChief Financial Officer
- PSPierre S. SayadChief Medical Officer
- TETerry EvansChief Commercial Officer
- CCChristiana CioffiChief Strategy Officer
- CAChris A. RallisIndependent Director
- MMMarco Maria BrugheraIndependent Director
- JAJodi Ann CookIndependent Director
- Company NameGain Therapeutics, Inc.Stock CodeGANXPositionChairman & Founder
